Summary
In sixteen patients with arterial hypertension and differing degrees of renal function the pharmacokinetics and haemodynamic effects of nitrendipine have been studied after treatment for 7 days. The AUC (0–24) and the elimination half-life of nitrendipine were significantly increased; the AUC (0–24) in patients with renal failure (median creatinine clearance 27.1 ml × min−1) was 196 ng × ml−1 × h compared to 97.8 ng × ml−1 × h in control subjects (median creatinine clearance 94.4 ml × min−1). The corresponding elimination half-lives were 13.5 h in renal failure and 4.4 h in the controls. The haemodynamic effects of nitrendipine were not enhanced in the patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aronoff GR (1984) Pharmacokinetics of nitrendipine in patients with renal failure in comparison to normal subjects. J Cardiovasc Pharmacol 6: 974–976
Aronoff GR, Sloan RS (1985) Nitrendipine kinetics in normal and impaired renal function. Clin Pharmacol Ther 38: 212–218
Braunwald E (1982) Mechanism of action of calcium channel blocking agents. N Engl J Med 307: 1618–1627
Dal Canton A, Esposito C, Sabbatini M, Altomonte M, Romano R, Veniero P, Uccello F, Andreucci VE (1986) Effects of nitrendipine in patients with chronic renal failure. Am J Nephrol 6 [Suppl 1]: 162–164
Edgar B, Regardh CG, Attman PO, Aurell M, Herlitz H, Johnsson G (1988) Pharmacokinetics of felodipine in patients with renal failure. In: Edgar B (ed) Clinical pharmacokinetics of felodipine. Vasastadens Bokbinderei AS Göteborg: 1–18
Dylewicz P, Kirch W, Santos SR, Hutt HJ, Mönig H, Ohnhaus EE (1987) Bioavailability and elimination of nitrendipine in liver disease. Eur J Clin Pharmacol 32: 563–568
Hermsmeyer K, Kuthe C (1984) Calcium antagonists and excitations of the vascular muscle membrane. J Cardiovasc Pharmacol 6: S933-S936
Janis RA, Sarmiento JG, Maurer SC, Bolger GT, Triggle DJ (1984) Characteristics of the binding of (3H)-nitrendipine to rabbit ventricular membranes: Modification by other Ca2+-channel antagonists and by the Ca2+-antagonist Bay K 8644. J Pharmacol Exp Ther 231: 8–15
Kann J, Krol GJ, Rämsch KD, Burkholder DE, Levitt MJ (1984) Bioequivalence and metabolism of nitrendipine administered orally to healthy volunteers. J Cardiovasc Pharmacol 6: S968-S973
Kazda S, Garthoff B, Luckhaus G (1984) Mode of antihypertensive action of nitrendipine. J Cardiovasc Pharmacol 6: S956-S962
Kirch W, Köhler H, Berggren G, Braun W (1984) The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite. Clin Nephrol 18: 88–94
Kirch W, Köhler H, Mutschler E, Schäfer M (1981) Pharmacokinetics of atenolol in relation to renal function. Eur J Clin Pharmacol 19: 65–71
Kirch W, Hutt HJ, Heidemann H, Rämsch KD, Janisch HD, Ohnhaus EE (1984) Drug interactions with nitrendipine. J Cardiovasc Pharmacol 6: S982-S985
Kirch W, Rämsch KD, Dührsen U, Ohnhaus EE (1984) Clinical pharmacokinetics of nimodipine in normal and impaired renal function. Int J Clin Pharmacol Res 4: 381–384
Kleinbloesem DH, von Brummelen P, von Harten J, Danhof M, Breimer DD (1985) Nifedipine, influence of renal function on pharmacokinetic/hemodynamic relationship. Clin Pharmacol Ther 37: 563–574
Kuhn H, Loogen F (1980) Die Bestimmung der systolischen Zeitintervalle. Dtsch Med Wochenschr 105: 214–218
Lasseter KC, Shamblen EC, Murdoch AA, Burkholder DE, Krol GJ, Taylor RJ, Vanov SK (1984) Steady-state pharmacokinetics in hepatic insufficiency. J Cardiovasc Pharmacol 6: S977-S981
Lowenthal DT, Briggs WA, Gibson TP, Nelson H, Cirksenas J (1974) Pharmacokinetic of oral propranolol in chronic renal disease. Clin Pharmacol Ther 16: 761–769
Mast V, Fischer C, Machleidt C, Kuhlmann C (1988) Pharmacokinetics, bioavailability and antihypertensive properties of nitrendipine in patients with chronic renal failure. Naunyn-Schmiedebergs Arch Pharmacol 337 [Suppl R 125], Abstr. 499
Rämsch KD, Sommer J (1984) Pharmacokinetics and metabolism of nitrendipine. In: Scriabine A (ed) Nitrendipine. Urban & Schwarzenberg, Baltimore-Munich, pp 409–421
Rämsch KD, Gräfe KH, Scherling D, Sommer J, Ziegler R (1986) Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine and nimodipine. Am J Nephrol 6 [Suppl 1]: 73–80
Sachs L (1984) Applied statistics 2nd edn. Springer, Berlin Heidelberg New York Tokio, pp 395–403; 293–303
Scriabine A, Anderson CL, Janis RA, Kojima K, Rasmussen H, Lee S, Michal V (1984) Some recent pharmacological findings with nitrendipine. J Cardiovasc Pharmacol 6: S937-S943
Thompson EN, Williams R (1965) Effect of age upon liver function with particular reference to bromsulphthalein excretion. Gut 6: 266–270
Wagner JG (1975) Fundamentals of clinical pharmacokinetics. Drug Intelligence Publications, Hamilton, Illinois
Weissler AM, Harris WS, Schoenfeld CD (1968) Systolic time intervals in heart failure in man. Circulation 37: 149–159
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ankermann, T., Osterkamp, U., Santos, S.R. et al. Elimination and haemodynamic effects of nitrendipine in patients with chronic renal failure. Eur J Clin Pharmacol 36, 433–437 (1989). https://doi.org/10.1007/BF00558065
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00558065